<DOC>
	<DOCNO>NCT00379015</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epirubicin , cyclophosphamide , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving chemotherapy monoclonal antibody surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give epirubicin cyclophosphamide follow docetaxel trastuzumab work treat woman HER2-positive stage IIIB , stage IIIC , stage IV primary breast cancer .</brief_summary>
	<brief_title>Epirubicin Cyclophosphamide Followed By Docetaxel Trastuzumab Treating Women With HER2-Positive Stage III Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pathological complete response woman HER2-positive stage IIIB-IV breast cancer treat neoadjuvant epirubicin hydrochloride cyclophosphamide follow docetaxel trastuzumab ( Herceptin® ) . Secondary - Determine clinical response patient treat regimen . - Determine recurrence-free survival patient treat regimen . - Determine overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive epirubicin hydrochloride cyclophosphamide week 1-3 . Treatment epirubicin hydrochloride cyclophosphamide repeat every 3 week 4 course . Patients receive docetaxel week 13 trastuzumab ( Herceptin® ) week 13-15 . Treatment docetaxel trastuzumab repeat every 3 week 4 course . Patients undergo appropriate surgery . After surgery , patient hormone receptor-positive disease receive trastuzumab weekly either tamoxifen without luteinizing hormone-releasing hormone agonist aromatase inhibitor . Treatment continue 40 week . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary breast cancer Stage IIIB , IIIC , IV disease No inflammatory disease HER2 overexpressing tumor assess immunohistochemistry and/or fluorescent situ hybridization Hormone receptor status know PATIENT CHARACTERISTICS : Female Menopausal status specify Performance status 01 WBC ≤ 10,000/mm³ Absolute neutrophil count ≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.5 g/dL SGOT/SGPT ≤ 60 IU/L Bilirubin ≤ 1.5 mg/dL Creatinine ≤ 1.5 mg/dL LVEF ≥ 55 % No sign pneumonitis PRIOR CONCURRENT THERAPY : No prior surgery except biopsy No prior concurrent chemotherapy and/or hormonal therapy No prior concurrent biological therapy No prior concurrent radiotherapy except postoperative radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>